Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26 week randomized, open label, multi-center study of the efficacy and safety of telbivudine 600 mg once daily versus adefovir dipivoxil 10mg once daily in subjects with compensated chronic hepatitis B and sub-optimal response to at least 48 weeks of adefovir dipivoxil 10 mg.

Next Previous
X
Search
Trial Profile

A 26 week randomized, open label, multi-center study of the efficacy and safety of telbivudine 600 mg once daily versus adefovir dipivoxil 10mg once daily in subjects with compensated chronic hepatitis B and sub-optimal response to at least 48 weeks of adefovir dipivoxil 10 mg.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 May 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telbivudine (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 09 May 2011 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 07 Mar 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 29 Feb 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top